SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (627)9/1/1997 4:34:00 PM
From: D.Right   of 2173
 
Dear Henry:

Thanks for your post. It is nice to know. As I said in my post that Targretin may be a great drug for diabetes in the future. However don't we agree that LGND has not completed its first clinical trial II of Targretin for type II diabetes and the potential FDA approval for diabetic treatment is many many years away? I know you are a LGND fan and I like that company, too. But for diabetic patients and for investers interested in the diabetic field AMLN is a much better choice with the medicine coming out in a not too far future from now.

Regards

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News